SCHEMBL12380452

SCHEMBL12380452

O=S(=O)(CCl)Oc1ccc(N(CCCl)CCCl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.40
ERBB2 P04626 4/20 0.40
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HIF1A Q16665 3/20 0.40
LMNA P02545 3/20 0.40
MAPT P10636 2/20 0.40
NFKB1 P19838 2/20 0.40
THPO P40225 2/20 0.40
PMP22 Q01453 2/20 0.40
GMNN O75496 1/20 0.40
CYP2D6 P10635 1/20 0.40
GABRA1 P14867 1/20 0.40
TSHR P16473 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40
SLCO1B3 Q9NPD5 1/20 0.40
CYP3A4 P08684 3/20 0.39
ALOX15 P16050 2/20 0.39
ABCB11 O95342 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12421881 0.75 KEAP1 (0.33) ALDH1A1MEN1KMT2A
SCHEMBL12380453 0.73 HTT (0.36) CNR2CA1CA2CA9
SCHEMBL23931022 0.72 GAA (0.41) LMNAMEN1KMT2ACA12CA1
SCHEMBL659196 0.72 CA12 (0.46) EGFRERBB2ALDH1A1SMN1; SMN2HIF1A
SCHEMBL6252538 0.71 KMT2A (0.61) ALDH1A1LMNATSHRTDP1KDM4E
SCHEMBL3225090 0.71 CNR2 (0.48) EGFRERBB2ALDH1A1SMN1; SMN2HIF1A
SCHEMBL8508241 0.70 EGFR (0.47) EGFRERBB2ALDH1A1SMN1; SMN2HIF1A
SCHEMBL4292409 0.70 SRC (0.47) EGFRERBB2ALDH1A1SMN1; SMN2HIF1A
SCHEMBL28030772 0.69 CA2 (0.58) TDP1MEN1KMT2ACA12CA1
SCHEMBL10686398 0.69 EGFR (0.50) EGFRERBB2ALDH1A1SMN1; SMN2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309554-B2 Hypoxia activated drugs of nitrogen mustard alkylators THRESHOLD PHARMACEUTICALS (US) 2012-11-13 US disclosed
US-8309554-B2 Hypoxia activated drugs of nitrogen mustard alkylators THRESHOLD PHARMACEUTICALS (US) 2012-11-13 US disclosed
US-20110190310-A1 Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators THRESHOLD PHARMACEUTICALS, INC. 2011-08-04 US disclosed
US-20110190310-A1 Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators THRESHOLD PHARMACEUTICALS, INC. 2011-08-04 US disclosed
WO-2009140553-A2 HYPOXIA ACTIVATED DRUGS OF NITROGEN MUSTARD ALKYLATORS THRESHOLD PHARMACEUTICALS, INC. (US) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190310-A1 Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators HIF1AN, HIF1A, HYOU1 EGFR 303/4885ERBB2 201/4885ALDH1A1 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.